SCHEMBL3839883

SCHEMBL3839883

Cn1nc2c(-c3ccc(Cl)cc3Cl)cccc2c1Cc1nnn[nH]1

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 16/20 0.42
HSD11B1 P28845 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3839904 0.91 CRHR1 (0.41) CRHR1HSD11B1
SCHEMBL3843720 0.82 CRHR1 (0.43) CRHR1
SCHEMBL3839340 0.81 CRHR1 (0.42) CRHR1HSD11B1
SCHEMBL3843569 0.81 CRHR1 (0.44) CRHR1HSD11B1
SCHEMBL3846212 0.80 CRHR1 (0.44) CRHR1HSD11B1
SCHEMBL3839128 0.80 CRHR1 (0.51) CRHR1HSD11B1
SCHEMBL3843571 0.79 CRHR1 (0.42) CRHR1HSD11B1
SCHEMBL3364388 0.79 CRHR1 (0.48) CRHR1HSD11B1
SCHEMBL3839810 0.79 CRHR1 (0.44) CRHR1HSD11B1
SCHEMBL3364574 0.79 CRHR1 (0.50) CRHR1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007753-B1 HETEROCYCLIC GABA ALPHA SUBTYPE SELECTIVE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2009-11-11 EP disclosed
US-20070238765-A1 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC 2007-10-11 US disclosed
US-20070238765-A1 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC 2007-10-11 US disclosed
US-20070238765-A1 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238765-A1 Heterocyclic GABAA subtype selective receptor modulators GABRA1, GABRA2, GABRA3 CRHR1 96/4885HSD11B1 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.